Related to this, drug–drug interaction testing showed that the association of SGLT2 inhibitors with drugs such as DDP inhibitors, statins, angiotensin II receptor blockers and calcium channel blockers increased the risk of urinary tract infections in diabetic patients [48]. This evidence concerns the gene SLC5A2 and urinary tract infection.